Selumetinib
 | |
| Clinical data | |
|---|---|
| Other names | AZD6244, ARRY-142886 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.169.311 |
| Chemical and physical data | |
| Formula | C17H15BrClFN4O3 |
| Molar mass | 457.68 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Selumetinib (AZD6244) is a drug being investigated for the treatment of various types of cancer, for example non-small cell lung cancer (NSCLC).
Mechanism of action
The gene BRAF is part of the MAPK/ERK pathway, a chain of proteins in cells that communicates input from growth factors. Activating mutations in the BRAF gene, primarily V600E (meaning that the amino acid valine in position 600 is replaced by glutamic acid), are associated with lower survival rates in patients with papillary thyroid cancer. Another type of mutation that leads to undue activation of this pathway occurs in the gene KRAS and is found in NSCLC. A possibility of reducing the activity of the MAPK/ERK pathway is to block the enzyme MAPK kinase (MEK), immediately downstream of BRAF, with the drug selumetinib. More specifically, selumetinib blocks the subtypes MEK1 and MEK2 of this enzyme.[1]
Possible uses
In addition to thyroid cancer, BRAF-activating mutations are prevalent in melanoma (up to 59%), colorectal cancer (5–22%), serous ovarian cancer (up to 30%), and several other tumor types.[2]
KRAS mutations appear in 20 to 30% of NSCLC cases and about 40% of colorectal cancer.[1]
A Phase II clinical trial about selumetinib in NSCLC has been completed in September 2011;[3] one about cancers with BRAF mutations is ongoing as of June 2012[update].[4]
References
- ^ a b PMID 22569000
- ^ PMID 12068308
- ^ Clinical trial number NCT00890825 for "Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients" at ClinicalTrials.gov
- ^ Clinical trial number NCT00888134 for "AZD6244 in Cancers With BRAF Mutations" at ClinicalTrials.gov
Further reading
- Ho, Alan L.; Grewal, Ravinder K.; Leboeuf, Rebecca; Sherman, Eric J.; Pfister, David G.; Deandreis, Desiree; Pentlow, Keith S.; Zanzonico, Pat B.; Haque, Sofia (2013). "Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer". New England Journal of Medicine. 368 (7): 623–32. doi:10.1056/NEJMoa1209288. PMID 23406027.